IFNA1 and neoplasm: To overcome these limitations, several strategies to prolong IFNα half-life and target the tumor microenvironment have been tested (Fioravanti et al., 2011; Herndon et al., 2012; Jeon et al., 2013; Li et al., 2017; Liang et al., 2018; Yang et al., 2014), including a preclinical gene/cell therapy approach that can deliver constant amounts of IFNα into the liver to significantly curb CRC metastatic growth (Catarinella et al., 2016).